.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,214,798

« Back to Dashboard

Details for Patent: 6,214,798

Title: GnRH antagonists being modified in positions 5 and 6
Abstract:Peptides are provided which have improved duration of GnRH antagonistic properties. These antagonists may be used to regulate fertility and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. These antagonists have a derivative of aminoPhe or its equivalent in the 5- or the 5- and 6-positions. This derivative is modified so as to contain a carbamoyl group or heterocycle, including a urea moiety, in its side chain. Decapeptides having the formula: wherein Q.sub.2 is Cbm or MeCbm and Xaa.sub.10 is D-Ala-ol or Ala-ol are particularly effective and continue to exhibit very substantial suppression of LH secretion at 96 hours following injection.
Inventor(s): Semple; Graeme (Gothenburg, SE), Jiang; Guangcheng (San Diego, CA)
Assignee: Ferring BV (Hoofddorp, NL)
Filing Date:Jan 03, 2000
Application Number:09/402,698
Claims:1. A GnRH antagonist peptide having the formula:

or a pharmaceutically acceptable salt thereof wherein:

X is an acyl group having not more than 7 carbon atoms or Q,

with Q being ##STR11##

and with R being H or lower alkyl;

A is 4Cl, 4F, 4Br, 4NO.sub.2, 4CH.sub.3, 4OCH.sub.3, 3,4Cl.sub.2 or C.sup..alpha. Me4Cl;

Xaa.sub.5 is 4Aph(Q.sub.1) or 4Amf(Q.sub.1) with Q.sub.1 being ##STR12##

a D/L mixture of either,

Xaa.sub.6 is D-4Aph(Q.sub.2), D-4Amf(Q.sub.2), D-Lys(Nic), D-Cit, D-Hci or D-3Pal, with Q.sub.2 being For, Ac, 3-amino-1,2,4-triazole(atz), Q or Q.sub.1 ;

Xaa.sub.8 is Lys(ipr), Arg, Har, Arg(Et.sub.2) or Har(Et.sub.2); and

Xaa.sub.10 is D-Ala-ol or Ala-ol; provided however that the .alpha.-amino group of Xaa.sub.5 may optionally be methylated; and provided further that when Xaa.sub.6 contains D- or L-Hor or D- or L-Imz or a D/L mixture of either, Xaa.sub.5 may have Ac, For or 3-amino-1,2,4-triazole as Q.sub.1.

2. A GnRH antagonist peptide according to claim 1 wherein Q is carbamoyl or methylcarbamoyl.

3. A GnRH antagonist according to claim 1 wherein Q.sub.1 is L-Hor or D-Hor.

4. A GnRH antagonist according to claim 1 wherein X is Ac and Xaa.sub.8 is Lys(ipr).

5. A GnRH antagonist according to claim 1 wherein Xaa.sub.5 is 4Aph(L- or D-Hor) and Xaa.sub.6 is D-4Aph(Ac), D-4Aph(atz), or D-3Pal.

6. A GnRH antagonist according to claim 1 wherein Xaa.sub.5 is 4Aph(L- or D-Hor), Q.sub.2 is Q and R is H or methyl.

7. A GnRH antagonist according to claim 1 wherein Xaa.sup.5 is 4Aph(L- or D-Hor) and Xaa.sub.6 is D-Cit or D-Hci.

8. A GnRH antagonist according to claim 1 wherein Xaa.sub.6 is D-4Aph(D-Hor).

9. A GnRH antagonist peptide according to claim 1 wherein:

X is For, Ac, Acr, Pn, By, Vl, Vac, Bz or Q;

A is 4Cl or 4F;

Xaa.sub.5 is 4Aph(Q.sub.1) or 4Amf(Q.sub.1) with Q.sub.1 being a D-isomer, an L-isomer, or a D/L-isomer mixture of either Hor or Imz;

Xaa.sub.6 is D-4Aph(Q.sub.2), D-4Amf(Q.sub.2), D-Cit, D-Lys(Nic) or D-3Pal, with Q.sub.2 being For, Ac, Q or Q.sub.1 ; and

Xaa.sub.8 is Lys(ipr).

10. A GnRH antagonist according to claim 9 wherein Q.sub.1 is L- or D-Hor and Xaa.sub.6 is D-4Amf(Q), with R being H or methyl.

11. A GnRH antagonist according to claim 9 wherein X is Ac or Q; R is H or methyl; Xaa.sub.6 is D-4Aph(Q.sub.2), D-4Amf(Q.sub.2) or D-3Pal, with Q.sub.2 being Ac, Q or Q.sub.1.

12. A GnRH antagonist according to claim 1 having the formula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-Xaa.sub.6 -Leu-Lys(ipr)-Pro-Xaa.sub.10, wherein Xaa.sub.6 is D-4Aph(Ac), D-3Pal, D-4Aph(carbamoyl), D-4Amf(carbamoyl), D-4Amf(methylcarbamoyl) or D-4Aph(D-Hor).

13. A pharmaceutical composition for inhibiting the secretion of gonadotropins in mammals comprising, as an active ingredient, an effective amount of a GnRH antagonist according to claim 12 in association with a nontoxic diluent.

14. A method for inhibiting the secretion of gonadotropins in mammals comprising administering an amount of a pharmaceutical composition according to claim 13 which effects a substantial decrease in LH and FSH levels.

15. A method for in vivo or in vitro diagnosis of a condition where GnRH is causing excess hormonal secretion or tumor growth, which method comprises administering a GnRH antagonist peptide according to claim 12 and monitoring for hormonal secretion or for tumor cell proliferation.

16. A GnRH antagonist according to claim 1 having either the formula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-D-4Aph(carbamoyl)-Leu-Lys(ipr)-Pro -D-Ala-ol; or the formula Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-D-4Aph(carbamoyl)-Leu-Lys(ipr)-Pro -Ala-ol.

17. A GnRH antagonist according to claim 1 having either the formula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-D-4Amf(carbamoyl)-Leu-Lys(ipr)-Pro -D-Ala-ol; or the formula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-D-4Amf(carbamoyl)-Leu-Lys(ipr)-Pro -Ala-ol.

18. A GnRH antagonist peptide having the formula:

or a pharmaceutically acceptable salt thereof wherein:

X is an acyl group having not more than 7 carbon atoms or Q,

with Q being ##STR13##

and with R being H or lower alkyl;

A is 4Cl, 4F, 4Br, 4NO.sub.2, 4CH.sub.3, 4OCH.sub.3, 3,4Cl.sub.2 or C.sup..alpha. Me4Cl;

Xaa.sub.5 is 4Aph(Q.sub.1) or 4Amf(Q.sub.1) with Q.sub.1 being ##STR14##

or a D/L mixture of either,

Xaa.sub.6 is D-4Aph(Q.sub.2), D-4Amf(Q.sub.2), D-Lys(Nic), D-Cit, D-Hci or D-Pal, with Q.sub.2 being For, Ac, 3-amino-1,2,4-triazole, Q or Q.sub.1 ;

Xaa.sub.8 is Lys(ipr), Arg, Har, Arg(Et.sub.2) or Har(Et.sub.2); and

Xaa.sub.10 is D-Ala-NH.sub.2, D-Ala-ol, Ala-ol, NHCH.sub.2 CH.sub.3, Gly-NH.sub.2, Ala-NH.sub.2, AzaGly-NH.sub.2, Agl-NH.sub.2, D-Agl-NH.sub.2, Agl(Me)-NH.sub.2 or D-Agl(Me)-NH.sub.2, provided however that when Xaa.sub.6 contains D- or L-Hor or D- or L-Imz or a D/L mixture of either, Xaa.sub.5 may have Ac, For or 3-amino-1,2,4-triazole as Q.sub.1.

19. A GnRH antagonist peptide according to claim 18 wherein

Q is carbamoyl or methylcarbamoyl;

Q.sub.1 is L-Hor or D-Hor; and

Xaa.sub.10 is D-Ala-NH.sub.2, D-Ala-ol or Ala-ol.

20. A GnRH antagonist peptide according to claim 18 wherein:

X is For, Ac, Acr, Pn, By, Vl, Vac, Bz or Q;

A is 4Cl or 4F;

Xaa.sub.5 is Aph(Q.sub.1) or Amf(Q.sub.1) with Q.sub.1 being a D-isomer, an L-isomer, or a D/L-isomer mixture of either Hor or Imz;

Xaa.sub.6 is D-Aph(Q.sub.2), D-Amf(Q.sub.2), D-Cit, D-Lys(Nic) or D-Pal, with Q.sub.2 being For, Ac, Q or Q.sub.1 ; and

Xaa.sub.8 is Lys(ipr).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc